Microbiological and immunologic considerations with aerosolized drug delivery

Chest

Volumn 120, Issue 3 SUPPL., 2001, Pages 118S-123S

  LiPuma, J J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Aerosolized; Breakpoint; Cystic fibrosis; Gram negative pathogens; Minimal inhibitory concentration; Pseudomonas aeruginosa; Superinfection; Tobramycin

Indexed keywords

ANTIBIOTIC AGENT; DORNASE ALFA; PLACEBO; TOBRAMYCIN;

AEROSOL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIUM DETECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DEVICE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG PENETRATION; DRUG SENSITIVITY; DRUG SPUTUM LEVEL; GROWTH INHIBITION; HUMAN; IMMUNE RESPONSE; LONG TERM CARE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; STENOTROPHOMONAS MALTOPHILIA;

EID: 0034835277     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.120.3_suppl.118S     Document Type: Article

References (11)

1. Aminoglycoside penetration, inactivation and efficacy in cystic fibrosis sputum
2. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulized systems
3. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
4. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
5. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis
6. Aminoglycoside resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by chronic, intermittent, inhaled tobramycin treatment
7. Safety of inhaled proteins for therapeutic use
8. The effect of aerosolized recombinant DNase on respiratory exacerbations and pulmonary function in patients with cystic fibrosis
9. Suppression of IgE responses by antigen inhalation: Studies on the role of genetic and environmental factors
10. Pulmonary delivery of peptides and proteins for systemic action
11. Effect of nebulizer type and antibiotic concentration on device performance